A Norman cyclist who has lived with multiple sclerosis for nearly two decades is riding coast-to-coast to raise awareness and ...

A new community-led network called PRADA enables underrepresented patients living with MS to help set research priorities.

Real-world data show Ocrevus reduced relapse rates and maintained disability stability in relapsing MS over four years.

—Clinicians may be underestimating the cognitive burden on patients with MS, underscoring the need for more comprehensive cognitive assessments and assessing patient-reported outcomes. A growing body ...

Resistance training is effective for improving gait speed in individuals with multiple sclerosis. The intensity and duration of resistance training are important factors in determining the magnitude ...

To provide the right treatment for multiple sclerosis (MS), it is important to know when the disease changes from relapsing-remitting to secondary progressive, a transition that is currently ...

About 1 million people are living with multiple sclerosis in the U.S., and about 10% of those have PPMS, making it the least common form of the disease.

Ublituximab shows five year relapse reduction and disability benefits in multiple sclerosis, supporting early high efficacy treatment strategies today.

Multiple sclerosis is a central nervous system autoimmune condition that damages myelin sheath that protects the nervous system, affects brain and spinal cord and leads to aggravated conditions like ...

For the first 10 years after Sarah Hwang’s multiple sclerosis diagnosis in 1999, she had a relapsing form of the disorder. Relapses came with blurred vision or numbness in one of her limbs. Then, ...

NESS ZIONA, Israel, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting ...